A clinical, hematologic, and immunologic analysis of 21 HTLV-II-infected intravenous drug users

Joseph D Rosenblatt, Susan Plaeger-Marshall, Janis V. Giorgi, Priscilla Swanson, Irvin S Y Chen, Eva Chin, HeJing Wang, Michel Canavaggio, Alexander C. Black, Helen Lee

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Infection with human T-cell leukemia virus type II (HTLV-II) has been associated with rare chronic T-cell malignancies and has recently been demonstrated in a significant proportion of American intravenous drug abusers (IVDA). Identification of an HTLV-II-infected cohort of IVDA has allowed analysis of the HTLV-II carrier state. We analyzed clinical, hematologic, and immunologic parameters in 21 HTLV-II-infected IVDA, two HTLV-I-infected IVDA, and 20 uninfected control IVDA identified by serologic screening and by analysis of peripheral blood mononuclear cell (PBMC) DNA by polymerase chain reaction (PCR). An elevated absolute lymphocyte count was observed in 4 of 21 HTLV-II-infected IVDA, 1 of 2 HTLV-I-infected IVDA, and 1 of 20 control IVDA. CD8+ T-cell elevation was observed in three of four HTLV-II IVDA with lymphocytosis and one of two HTLV-I-infected IVDA. Activation of CD8+ T cells in HTLV-II-infected IVDA was suggested by an overall increase in CD8+/HLA-DR+ lymphocytes. Cell fractionation and analysis by PCR of HTLV-II-infected carrier blood showed high levels of HTLV-II provirus in unfractionated PBMC and purified T cells and little or no detectable HTLV-II DNA in B cells or monocytes, indicating that T cells were the most likely target of infection in vivo. The frequency of HTLV-II-infected cells was estimated at approximately 1 in 500 cells or less using dilution analysis by PCR of PBMC DNA. Most HTLV-II-infected IVDA are asymptomatic and have no overt hematologic or immunologic abnormalities, although some manifest benign lymphocytosis.

Original languageEnglish
Pages (from-to)409-417
Number of pages9
JournalBlood
Volume76
Issue number2
StatePublished - Jul 15 1990
Externally publishedYes

Fingerprint

Human T-lymphotropic virus 2
T-cells
Drug Users
Viruses
Pharmaceutical Preparations
Human T-lymphotropic virus 1
T-Lymphocytes
Lymphocytosis
Blood Cells
Polymerase chain reaction
Blood
Polymerase Chain Reaction
Lymphocytes
Cell Fractionation
Carrier State
Proviruses
DNA
Lymphocyte Count
HLA-DR Antigens
DNA-Directed DNA Polymerase

ASJC Scopus subject areas

  • Hematology

Cite this

Rosenblatt, J. D., Plaeger-Marshall, S., Giorgi, J. V., Swanson, P., Chen, I. S. Y., Chin, E., ... Lee, H. (1990). A clinical, hematologic, and immunologic analysis of 21 HTLV-II-infected intravenous drug users. Blood, 76(2), 409-417.

A clinical, hematologic, and immunologic analysis of 21 HTLV-II-infected intravenous drug users. / Rosenblatt, Joseph D; Plaeger-Marshall, Susan; Giorgi, Janis V.; Swanson, Priscilla; Chen, Irvin S Y; Chin, Eva; Wang, HeJing; Canavaggio, Michel; Black, Alexander C.; Lee, Helen.

In: Blood, Vol. 76, No. 2, 15.07.1990, p. 409-417.

Research output: Contribution to journalArticle

Rosenblatt, JD, Plaeger-Marshall, S, Giorgi, JV, Swanson, P, Chen, ISY, Chin, E, Wang, H, Canavaggio, M, Black, AC & Lee, H 1990, 'A clinical, hematologic, and immunologic analysis of 21 HTLV-II-infected intravenous drug users', Blood, vol. 76, no. 2, pp. 409-417.
Rosenblatt JD, Plaeger-Marshall S, Giorgi JV, Swanson P, Chen ISY, Chin E et al. A clinical, hematologic, and immunologic analysis of 21 HTLV-II-infected intravenous drug users. Blood. 1990 Jul 15;76(2):409-417.
Rosenblatt, Joseph D ; Plaeger-Marshall, Susan ; Giorgi, Janis V. ; Swanson, Priscilla ; Chen, Irvin S Y ; Chin, Eva ; Wang, HeJing ; Canavaggio, Michel ; Black, Alexander C. ; Lee, Helen. / A clinical, hematologic, and immunologic analysis of 21 HTLV-II-infected intravenous drug users. In: Blood. 1990 ; Vol. 76, No. 2. pp. 409-417.
@article{273e97a408f14f8fb993da428b5cf94a,
title = "A clinical, hematologic, and immunologic analysis of 21 HTLV-II-infected intravenous drug users",
abstract = "Infection with human T-cell leukemia virus type II (HTLV-II) has been associated with rare chronic T-cell malignancies and has recently been demonstrated in a significant proportion of American intravenous drug abusers (IVDA). Identification of an HTLV-II-infected cohort of IVDA has allowed analysis of the HTLV-II carrier state. We analyzed clinical, hematologic, and immunologic parameters in 21 HTLV-II-infected IVDA, two HTLV-I-infected IVDA, and 20 uninfected control IVDA identified by serologic screening and by analysis of peripheral blood mononuclear cell (PBMC) DNA by polymerase chain reaction (PCR). An elevated absolute lymphocyte count was observed in 4 of 21 HTLV-II-infected IVDA, 1 of 2 HTLV-I-infected IVDA, and 1 of 20 control IVDA. CD8+ T-cell elevation was observed in three of four HTLV-II IVDA with lymphocytosis and one of two HTLV-I-infected IVDA. Activation of CD8+ T cells in HTLV-II-infected IVDA was suggested by an overall increase in CD8+/HLA-DR+ lymphocytes. Cell fractionation and analysis by PCR of HTLV-II-infected carrier blood showed high levels of HTLV-II provirus in unfractionated PBMC and purified T cells and little or no detectable HTLV-II DNA in B cells or monocytes, indicating that T cells were the most likely target of infection in vivo. The frequency of HTLV-II-infected cells was estimated at approximately 1 in 500 cells or less using dilution analysis by PCR of PBMC DNA. Most HTLV-II-infected IVDA are asymptomatic and have no overt hematologic or immunologic abnormalities, although some manifest benign lymphocytosis.",
author = "Rosenblatt, {Joseph D} and Susan Plaeger-Marshall and Giorgi, {Janis V.} and Priscilla Swanson and Chen, {Irvin S Y} and Eva Chin and HeJing Wang and Michel Canavaggio and Black, {Alexander C.} and Helen Lee",
year = "1990",
month = "7",
day = "15",
language = "English",
volume = "76",
pages = "409--417",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - A clinical, hematologic, and immunologic analysis of 21 HTLV-II-infected intravenous drug users

AU - Rosenblatt, Joseph D

AU - Plaeger-Marshall, Susan

AU - Giorgi, Janis V.

AU - Swanson, Priscilla

AU - Chen, Irvin S Y

AU - Chin, Eva

AU - Wang, HeJing

AU - Canavaggio, Michel

AU - Black, Alexander C.

AU - Lee, Helen

PY - 1990/7/15

Y1 - 1990/7/15

N2 - Infection with human T-cell leukemia virus type II (HTLV-II) has been associated with rare chronic T-cell malignancies and has recently been demonstrated in a significant proportion of American intravenous drug abusers (IVDA). Identification of an HTLV-II-infected cohort of IVDA has allowed analysis of the HTLV-II carrier state. We analyzed clinical, hematologic, and immunologic parameters in 21 HTLV-II-infected IVDA, two HTLV-I-infected IVDA, and 20 uninfected control IVDA identified by serologic screening and by analysis of peripheral blood mononuclear cell (PBMC) DNA by polymerase chain reaction (PCR). An elevated absolute lymphocyte count was observed in 4 of 21 HTLV-II-infected IVDA, 1 of 2 HTLV-I-infected IVDA, and 1 of 20 control IVDA. CD8+ T-cell elevation was observed in three of four HTLV-II IVDA with lymphocytosis and one of two HTLV-I-infected IVDA. Activation of CD8+ T cells in HTLV-II-infected IVDA was suggested by an overall increase in CD8+/HLA-DR+ lymphocytes. Cell fractionation and analysis by PCR of HTLV-II-infected carrier blood showed high levels of HTLV-II provirus in unfractionated PBMC and purified T cells and little or no detectable HTLV-II DNA in B cells or monocytes, indicating that T cells were the most likely target of infection in vivo. The frequency of HTLV-II-infected cells was estimated at approximately 1 in 500 cells or less using dilution analysis by PCR of PBMC DNA. Most HTLV-II-infected IVDA are asymptomatic and have no overt hematologic or immunologic abnormalities, although some manifest benign lymphocytosis.

AB - Infection with human T-cell leukemia virus type II (HTLV-II) has been associated with rare chronic T-cell malignancies and has recently been demonstrated in a significant proportion of American intravenous drug abusers (IVDA). Identification of an HTLV-II-infected cohort of IVDA has allowed analysis of the HTLV-II carrier state. We analyzed clinical, hematologic, and immunologic parameters in 21 HTLV-II-infected IVDA, two HTLV-I-infected IVDA, and 20 uninfected control IVDA identified by serologic screening and by analysis of peripheral blood mononuclear cell (PBMC) DNA by polymerase chain reaction (PCR). An elevated absolute lymphocyte count was observed in 4 of 21 HTLV-II-infected IVDA, 1 of 2 HTLV-I-infected IVDA, and 1 of 20 control IVDA. CD8+ T-cell elevation was observed in three of four HTLV-II IVDA with lymphocytosis and one of two HTLV-I-infected IVDA. Activation of CD8+ T cells in HTLV-II-infected IVDA was suggested by an overall increase in CD8+/HLA-DR+ lymphocytes. Cell fractionation and analysis by PCR of HTLV-II-infected carrier blood showed high levels of HTLV-II provirus in unfractionated PBMC and purified T cells and little or no detectable HTLV-II DNA in B cells or monocytes, indicating that T cells were the most likely target of infection in vivo. The frequency of HTLV-II-infected cells was estimated at approximately 1 in 500 cells or less using dilution analysis by PCR of PBMC DNA. Most HTLV-II-infected IVDA are asymptomatic and have no overt hematologic or immunologic abnormalities, although some manifest benign lymphocytosis.

UR - http://www.scopus.com/inward/record.url?scp=0025338552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025338552&partnerID=8YFLogxK

M3 - Article

C2 - 1973360

AN - SCOPUS:0025338552

VL - 76

SP - 409

EP - 417

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -